56
NICE has said Biogen’s Tysabri can now be used by the NHS in England and Wales to treat highly active relapsing-remitting multiple sclerosis (MS), along with a lower-cost biosimilar version of the drug.
The new draft guidance (PDF) covers the use of Biogen’s original Tysabri brand of natalizumab and Sandoz and Polpharma Biologics’ biosimilar equivalent Tyruko, which was approved in 2023.
The document notes that either version of natalizumab can be used in patients with highly active relapsing-remitting MS who have not responded to a full and adequate course of at least one other…